Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00073307
Status:
COMPLETED
Last Update Posted:
2014-02-06
First Post:
2003-11-19
Brief Title:
Study of BAY43-9006 in Patients With Unresectable andor Metastatic Renal Cell Cancer
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable andor Metastatic Renal Cell Cancer
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate safety efficacy including quality of life and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable andor metastatic renal cell cancer who have received one prior systemic regimen for advanced disease
Detailed Description:
Overall Survival OS Patient-reported outcome PRO
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None